Cancer treatment is not a one-time decision, it is an ongoing journey that requires constant monitoring. OncoMonitor® by 1Cell.Ai is a liquid biopsy test that tracks how cancer is responding to treatment, using just a blood sample. By measuring circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) over time, oncologists can see in real time whether a therapy is working, if resistance is building, or if the disease is returning, often before it shows up on a scan.
For patients, this means fewer invasive procedures and faster, more personalized care. For oncologists, it means data-driven decisions backed by AI-powered reporting through the iCARE platform. OncoMonitor® covers two key needs: treatment response monitoring through OncoMonitor® TRM and minimal residual disease detection through OncoMonitor® MRD, applicable across cancers like lung, breast, colorectal, ovarian, and more.
Download our white paper to understand the clinical evidence, validation results, and how longitudinal liquid biopsy monitoring can change outcomes for your patients.